Gilead Sciences

This phase 3 trial tests whether a combination of two antibodies (teropavimab and zinlirvimab) plus the drug lenacapavir, given as injections twice a year, can keep HIV under control in adults whose virus is already well-suppressed by daily oral medication. The study compares thi…

This study tests whether an injectable combination of two experimental drugs, GS-3242 and lenacapavir, can control HIV-1 as well as the daily pill Biktarvy. About 700 people with HIV who have never taken antiviral treatment will receive either the injectable regimen or the standa…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…

This Phase 3 trial tests whether seladelpar, a daily pill, can improve outcomes for people with primary biliary cholangitis (PBC) who also have compensated cirrhosis. About 318 adults will receive either seladelpar or a placebo for up to 36 months. The study tracks serious events…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This Phase 2 trial tests whether switching to a combination of two injectable drugs, GS-3242 and lenacapavir, works as well as staying on the daily pill Biktarvy for people with HIV who already have the virus under control. About 175 participants will be randomly assigned to eith…

This early-stage trial tests an oral drug called GS-2426 in people with advanced solid tumors that lack a gene called MTAP. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 174 adults whose cancer has not responded to standard t…

This phase 3 trial tests whether a combination of two broadly neutralizing antibodies (teropavimab and zinlirvimab) plus a capsid inhibitor (lenacapavir), given as injections just twice a year, can keep HIV under control as well as daily oral medications. The study enrolls adults…

This study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the disease will receive multiple doses to see if the drug can reduce virus levels and improve liver hea…

This phase 2 trial tests a new drug called denikitug, alone or combined with other treatments, in 170 people with advanced microsatellite stable (MSS) colorectal cancer. MSS colorectal cancer is a common type that often does not respond to standard immunotherapy. The study aims t…

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) given after surgery works better than standard treatments to prevent breast cancer from coming back. It is for people with triple negative breast cancer who still have cancer cells in th…

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …

This early-phase study tests a new oral drug called GS-4571 in healthy people, non-diabetic obese individuals, and non-obese people with type 2 diabetes. The main goals are to see how the drug moves through the body, how safe it is, and how food or acid-reducing drugs affect it. …

This early-phase study tests a new drug called GS-5319 in adults with advanced solid tumors that lack a specific gene (MTAP). The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 178 people whose cancer has not responded to s…

This study offers continued access to HIV medications for children and adolescents who completed a previous Gilead HIV treatment study. About 350 participants will receive their study drug or switch to a standard HIV medication, and researchers will monitor for side effects. The …

This early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.

This early-stage trial is testing the drug sacituzumab govitecan in 30 people with advanced solid tumors who also have moderate liver impairment. The main goal is to find a safe starting dose by monitoring side effects and how the drug moves through the body. Participants receive…

This study tests a long-acting HIV medicine called lenacapavir (Sunlenca®) in 12 adolescents and children with HIV who have tried other treatments. Participants take lenacapavir as pills and injections along with their other HIV drugs. The goal is to see if the combination is saf…

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …

This study tests a drug called sacituzumab govitecan in people with advanced bladder cancer that has spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the cancer. About 827 adults with good organ function and a life expectancy o…

This study tests an experimental oral drug called GS-5290 (tilpisertib fosmecarbil) in 176 adults with moderate to severe ulcerative colitis. Participants are randomly assigned to receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can improve s…

This study tests a different dose and schedule of the drug sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has not responded to prior treatment. The trial has two phases: phase 1 checks safety and the best dose, and phase 2 measures how…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This study looks at how well people stick to a new HIV prevention shot called lenacapavir. About 3,000 people in the U.S. who want or need HIV prevention will take part. Researchers will track who stays on the shot and how it works in everyday clinic settings.